Iterum Therapeutics plc Overview
Pro stress-test →Iterum Therapeutics is an Ireland-headquartered pharmaceutical company dedicated to developing anti-infective treatments targeting multi-drug resistant (MDR) pathogens. The company achieved a major milestone in October 2024 when the FDA approved Orlynvah, the first and only approved oral penem antibiotic, addressing a critical gap in treating uncomplicated urinary tract infections for patients with limited treatment alternatives.
Strategic Profile
Pro stress-test →Iterum occupies a unique position in the specialized anti-infectives market, leveraging FDA designations and clinical expertise to address the growing global crisis of antimicrobial resistance. The company's pipeline includes sulopenem in Phase 3 development with multiple oral and IV formulations targeting various serious infections, providing multiple revenue opportunities beyond the initial Orlynvah launch.
Competitive Landscape
Pro stress-test →Iterum competes in the specialized anti-infectives space against larger pharma players and biotech firms developing MDR-targeted treatments. Key competitors include major antibiotic manufacturers like Allergan (Vaborbactam combinations) and emerging biotech like Melinta Therapeutics and Spero Therapeutics. Iterum's differentiation lies in the novel oral penem class (Orlynvah) and broader pipeline coverage across multiple serious infections.
Industry Context
Iterum Therapeutics plc operates in Biotechnology/Specialty Pharmaceuticals - Anti-Infectives.
Key facts
Founded: 2015 · Headquarters: Dublin, Ireland · Employees: 11-50